Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results

Hims & Hers Health Inc (NYSE: HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.

Benzinga • 9 hours ago

Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft 2026 revenue guidance is keeping the stock under pressure after a sharp year-to-date selloff.

24/7 Wall Street • 15 hours ago

Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard

Shares of Hims & Hers Health ( NYSE:HIMS ) are trading lower this morning after yesterday's earnings, and the reason is straightforward: guidance.

24/7 Wall Street • 12 hours ago

Hims & Hers Q4 Earnings Show Growth Amid GLP-1 Scrutiny

Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces near-term margin pressure. Management guided FY26 revenue of $2.7–$2.9B and Adjusted EBITDA of $300–$375M, signaling continued investment in international expansion and new specialties over margin optimization. The SEC is investigating HIMS regarding disclosures about compounded semaglutide, introducing regulatory uncertainty and contributing to a 9% post-earnings stock decline.

Seeking Alpha • 15 hours ago

Hims & Hers Stock Stumbles - Cautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences

The stock's decline follows a report that revealed revenue missed analyst expectations, adding pressure as broader markets experienced slight gains on the previous trading day.

Benzinga • 13 hours ago

Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract

HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.

Zacks Investment Research • 8 hours ago

Hims & Hers Health After The GLP-1 Collapse

Hims & Hers Health's revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Operating cash flow reached $300M, with $929M in liquidity, reinforcing balance sheet strength. GLP-1 drove higher revenue per order, but most profitability remains in non-weight-loss categories.

Seeking Alpha • 13 hours ago

Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading

Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $617.8M (+28% YoY) and adjusted EBITDA of $66.3M, but subscriber growth and Q1 guidance disappointed due to GLP-1 headwinds. International expansion and labs initiatives are key growth drivers, with management targeting $1B+ annual international revenue and $1.3B adjusted EBITDA by 2030.

Seeking Alpha • 7 hours ago

Hims & Hers Health: Don't Get Lost In The Weeds

Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensus, and expects strong subscriber growth in weight loss offerings despite temporary GLP-1 headwinds. The Eucalyptus acquisition is set to add at least $200 million to 2026 revenues, positioning HIMS for a $3.25–$4 billion annualized run rate entering 2027.

Seeking Alpha • 6 hours ago

KDP Beats & HIMS Misses Sales, QCOM Gains on Upgrades

Keurig Dr. Pepper (KDP) didn't fizzle out when it came to earnings, with Diane King Hall noting a beat Tuesday morning. Hims & Hers (HIMS) couldn't do the same as the telehealth company sees headwinds as subscribers shrink.